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Abstract 
Background: Cyclosporine and tacrolimus are well established immunosuppressants; however 
little know about long term survival rates. Aim: Compare 10-year graft survival and associated 
factors among kidney transplant patients within the Brazilian Public Health system (SUS) 
prescribed either medicine. Methods: Analyze a national cohort of kidney transplant recipients 
within SUS. Graft loss defined by death or dialysis for more than three months. Kaplan-Meier 
method used to estimate cumulative probabilities of survival. Cox proportional hazards model 
used to evaluate factors associated with progression to graft loss. Results: 13,811 patients were 
included, 5,887 used cyclosporine and 7,924 tacrolimus. A higher risk of graft loss was 
associated with tacrolimus, a deceased donor, additional years of age, median period of dialysis 
greater than 47 months, diagnosis of diabetes as the primary cause of chronic kidney disease 
and transplantation between 2005 and 2009. Conclusions: Among other factors, tacrolimus-
based regimens were associated with worse graft survival. 
 
Introduction 
 
Chronic kidney disease (CKD) is characterized by slow, progressive, and irreversible loss of 
kidney function. The main causes include high blood pressure and diabetes mellitus. The 
number of patients with CKD worldwide has increased in recent decades, reaching epidemic 
proportions. The survival of patients with end-stage renal failure depends on the use of renal 
replacement therapy (RRT)(1-3). 
 
For patients with no contraindications, kidney transplantation is the best alternative among 
existing RRT options because it offers higher survival and better quality of life than dialysis, in 
addition to being more cost effective(4-6). Clinical outcomes of kidney transplantation have 
improved over the years, e.g. in the United States in 1998, one-year graft survival was 89.7% 
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with live-donor grafts and 76.0% with deceased-donor grafts; in 2014, these rates reached 
94.3% and 88.7%, respectively(7, 8).  
 
In 2012, Brazil ranked 31st in the number of living donor kidney transplantations per million 
inhabitants and 25th considering deceased donors among 71 countries. However in Latin 
America, Brazil occupied the 1st and 3rd places for transplantations with living and deceased 
donor grafts, respectively(13). 
 
The Unified Health System in Brazil (Sistema Único de Saúde, SUS) provides more than 95% of 
all transplantations performed in Brazil and, in accordance with the concept of comprehensive 
care, ensures access to immunosuppressants for transplant patients without co-payment(14). SUS 
also provides more than 84% of all dialysis performed in Brazil. According to the Clinical 
Protocol and Therapeutic Guidelines of the Brazilian Ministry of Health, maintenance 
immunosuppression among kidney transplant patients consists of a triple-drug regimen, 
typically containing a corticosteroid, a calcineurin inhibitor (cyclosporine or tacrolimus), and an 
antiproliferative agent (azathioprine, mycophenolate mofetil, or sodium mycophenolate)(15). 
Alternatively, either of the latter two drug classes can be replaced with mTOR inhibitors 
(sirolimus or everolimus), depending on the clinical characteristics of the patient(15, 16). 
Azathioprine and cyclosporine have been provided by SUS since 1982, tacrolimus and 
mycophenolate since 1990, sirolimus in 1999, and everolimus in 2008.he national 
transplantation program in Brazil, which provides medical procedures and post-transplantation 
medicines(16), is seen as successful with survival rates of SUS kidney transplant recipients 
similar to rates seen in developed countries(17).  
 
Calcineurin inhibitors are considered the hallmark immunosuppression. Despite their similar 
mechanisms of action, cyclosporine and tacrolimus have different pharmacokinetic profiles, 
which can translate into different benefits and side effects(18, 19). Both drugs are associated with 
long-term nephrotoxicity, but tacrolimus is associated with a higher incidence of post-transplant 
diabetes mellitus; whereas cyclosporine is associated with hyperlipidemia and hypertension(15, 
20, 21). 
 
Different approaches have been adopted to compare tacrolimus and cyclosporine. With regard 
to efficacy, a recent systematic review that included 26 randomized controlled trials involving 
6,054 patients reported a lower risk of acute rejection with tacrolimus; however, this did not 
translate into differences in one- to five-year graft survival between groups(19). Another 
systematic review that compared the effects of these two drugs as primary therapy for kidney 
transplant recipients found no difference between the two treatments after a five-year follow-
up(22).  
 
Graft loss is mainly due to death with a functioning graft (predominantly caused by 
cardiovascular events), glomerular disease (which may be recurrent), fibrosis/atrophy, acute 
rejection, and medical or surgical conditions, including recurrence of the disease that led to 
CKD(23). The occurrence of acute rejection during the first year after transplantation has been 
associated with worse long-term survival(24). However, Meier-Kriesche et al(25) evaluated 62,103 
kidney transplants and concluded that long-term (six-year period) graft survival and patient 
survival were not affected by decreased acute rejection rates. As a result, the authors criticized 
the use of acute rejection rates as the primary outcome in clinical trials.  In view of this, short 
term studies comparing tacrolimus and cyclosporine could be of limited benefit to provide 
guidance on their long term effectiveness and cost-effectiveness. Our initial study(26) with five 
years follow-up showed a clinical benefit for cyclosporine versus tacrolimus, with differences 
also seen in their relative cost-effectiveness with a paired analysis and five years follow-up  (27).  
 
However,  we wanted to look further at the Brazilian cohort, especially given the heterogeneity 
of the population in Brazil and concerns with shorter term studies, to provide further guidance to 
Ministry of Health personnel as well as physicians treating patients following kidney 
transplantation.  Consequently, the objective of this study is to evaluate up to 10-year graft 
survival of SUS kidney transplant patients who used either cyclosporine or tacrolimus.  
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Methods 
 
This non-concurrent open cohort study included patients who underwent kidney transplantation 
from living or deceased donors among all Brazilian transplantation centers. This cohort was 
developed by deterministic-probabilistic linkage of the following SUS administrative databases: 
Hospital Information System (SIH); Ambulatory Information System (SIA), and Mortality 
Information System (SIM)(26, 28-31). 
 
Patients who underwent kidney transplantation and received immunosuppressive regimens 
containing either cyclosporine or tacrolimus between January 1, 2000, and December 31, 2009, 
were included in the study. This entry period was established to ensure a minimum follow-up of 
12 months. The entry date was the date of transplantation registered in SIH.  
 
The event used for survival analysis was graft loss. This was defined as death or having had 
another kidney transplant or the need for dialysis for more than three months without 
concomitant use of immunosuppressive drugs. Patients were excluded if deaths occurred within 
six months of transplantation as this could be related to the surgical procedure rather than lack 
of effectiveness of immunosuppressive medicines in line with our previous study26. The event 
date was defined as the date of death, the date of re-transplantation or the last date of 
immunosuppressive treatment, whichever occurs first. We censored patients lost to follow-up as 
the date of the last recorded immunosuppressive treatment supply. Right censoring was 
established on 12/31/2010, i.e. the date of the event (death or return on dialysis) and the date of 
final entry (censoring right). In Brazil, mortality notification is mandatory, and continuous 
immunosuppressive treatment is dispensed to SUS patients on a monthly basis. Re-
transplantation was identified in the same way as the entry event (SIH) and dialysis is recorded 
in the same way as immunosuppressant therapy. 
 
We present descriptive statistics of all the study variables, i.e. frequency distribution for 
categorical variables and central tendency and variability for continuous variables. The variables 
included: (a) the region where the transplant was performed, (b) calendar year of 
transplantation categorised as 2000 to 2004 and 2005 to 2009, (c) gender, (d) age at the time of 
transplantation, (e) primary diagnosis of kidney disease, (f) treatment regimen (tacrolimus- or 
cyclosporine-based), (g) type of transplant received (living or deceased donor), and (h) period of 
GLDO\VLVSULRUWRNLGQH\WUDQVSODQWDWLRQ6WXGHQW¶VW-test was used to assess differences between 
the means of two groups, e.g. between the treatment regimens, and the chi-square test was 
used to evaluate differences in frequencies. 
 
We analyzed the factors that influenced graft survival using univariate analysis for each 
descriptive variable and evaluated their association with graft loss. The Kaplan-Meier method 
was used to estimate the cumulative probability of survival. The different survival curves were 
compared using the log-rank test. A value of p<0.20 was considered for inclusion of the variable 
in the multivariate model. The hazard ratio (HR) for progression to the event was calculated by 
univariate and multivariate analyses considering a 95% confidence interval (95% CI) and using 
the Cox proportional hazards model.  
 
Additionally, we performed a subgroup analysis according to donor type and treatment regimen 
(living donor/cyclosporine vs. living donor/tacrolimus and deceased donor/cyclosporine vs. 
deceased donor/tacrolimus) and an analysis considering only the return to dialysis as the event 
(death-censored graft loss analysis), focusing on the immunosuppressant agents tacrolimus 
and cyclosporine. We also performed supplementary analysis including all patients 
incorporating those who died within six months of transplantation as well as the use of either 
azathioprine or mycophenolate in addition to either cyclosporine or tacrolimus (Appendix). 
 
The statistical analysis was performed uVLQJ³5´YHUVLRQ (R Foundation for Statistical 
Computing) and SPSS version 17 (SPSS Inc., Chicago, USA) considering a significance level of 
5%.  
 
The study was approved by the Research Ethics Committee of the Universidade Federal de 
Minas Gerais (UFMG) (Approval number: 16334413.9.0000.5149).  
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Results 
 
From among 17,731 identified patients, the following were excluded: 1,181 for being younger 
than 18 years at the date of surgery, 322 for having underwent more than one transplantation 
during the study period, 2,044 for having switched calcineurin inhibitor (cyclosporine or 
tacrolimus) during the follow-up period, and 695 for having died within the first six months from 
the date of transplantation.  
 
Of the 13,811 patients included in the study, 5,887 (43%) used cyclosporine-based regimens 
and 7,924 (57%) used tacrolimus-based regimens. The majority of transplants were performed 
in Southeastern (62.5%) and Southern (20.9%) Brazil (Table 1). The number of patients 
entering the cohort on cyclosporine-based treatments decreased from 931 in 2000 to 244 in 
2009, whereas the number of those on tacrolimus treatment increased from 107 in 2000 to 
1,683 in 2009. Between 2000 and 2004, more patients were prescribed immunosuppression 
with cyclosporine-based regimens (68.0%) than with tacrolimus-based regimens (32.0%), and 
between 2005 and 2009 the opposite was observed, i.e. more patients were prescribed 
tacrolimus-based regimens (77.8%) than cyclosporine-based regimens (22.2%). 
 
Table 1. Demographic characteristics of study population. Brazil: 2000-2010 (N=13.811) 
 
Characteristic 
Total      
Cyclosporine- 
based  regimens   
Tacrolimus- 
based  regimens   
P 
(n= 13.811) (n= 5.887) (n= 7.924) 
n % n % n % 
Geographic origina 
 
      
 
<0,001 
Southeast 7.865 62.5 3.013 54.3 4.852 69 
 South 2.625 20.9 1.509 27.2 1.116 15.9 
 Northeast 1.352 10.7 636 11.5 716 10.2 
 Midwest 595 4.7 312 5.6 283 4.0 
 North 145 1.2 79 1.4 66 0.9 
         
Year of transplantation 
       
2000 a 2004 6.165 44.6 4.192 68.0 1.973 32.0 <0,001 
2005 a 2009 7.646 55.4 1.695 22.2 5.951 77.8  
 
        Recipient sex 
      
<0,001 
Female  8.316 60.2 3.815 64.8 4.501 56.8 
 Male 5.495 39.8 2.072 35.2 3.423 43.2 
         Age group (years)             <0,001 
18 - 29 2.838 20.6 1.155 19.6 1.683 21.2 
 30 - 39 3.485 25.2 1.603 27.2 1.882 23.8 
 40 - 49 3.640 26.4 1.563 26.6 2.077 26.2 
 50 - 64 3.499 25.3 1.425 24.2 2.074 26.2 
  349 2.5 141 2.4 208 2.6 
          Primary cause of Chronic Kidney Disease          <0,001 
Nephritisb 2.740 19.8 1.304 47.6 1.436 52.4 
 Hypertension / Cardiovascular Disease 2.453 17.8 1.167 47.6 1.286 52.4 
 Organ failure or rejection  737 5.3 332 45.0 405 55.0 
 Diabetes Mellitus  648 4.7 279 43.1 369 56.9 
 Kidney cystic disease/ Neoplasms / Tumors 278 2.0 123 44.2 155 55.8 
 Uropathies 188 1.4 83 42.8 111 57.2 
 Undetermined / Other causes 6.761 49.0 2.599 38.4 4.162 61.6 
         Donor type 
      
<0,001 
Living 7.527 54.5 3.570 47.4 3.597 52.6 
 Deceased 6.284 45.5 2.317 36.9 3.967 63.1 
        Time on dialysis prior to transplantation (months)a, c 
   
<0,001 
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 5.801 49.9 3.331 62.4 2.470 39.4 
 > 47 5.817 50.1 2.011 37.6 3.806 60.6 
         Events 
      
<0,001 
Censoringd 11.699 84.7 4.846 82.3 6.853 86.5 
 Graft loss  2.212 15.3 1.041 17.7 1.071 13.5 
     Death 967 7.0 512 8.7 455 5.7 
     Dialysis for more than 3 months 823 6.0 445 7.6 378 4.8  
  Re-transplant 322 2.3 84 1.4 238 3.0  
P-value refers to the comparison between groups (Pearson Chi2 test). In post hoc test of Geographic region, the following comparisons showed significant 
statistic difference: Southeast vs. Northeast; South vs. Northeast; and South vs. Midwest. For Age group the following comparisons showed statistic difference: 
(18 - 29) vs. (30 - 39); and (30 - 39) vs. (50 - 64). Primary cause of Chronic Kidney Disease showed significant statistic difference when comparing 
Undetermined / Other causes with the other categories.  
a Refers to individuals with valid data. 
b Glomerulonephritis / Interstitial nephritis / pyelonephritis.  
c Median time= 47 months. 
d Loss to follow-up or right censoring. 
 
The majority of the patients were women (60.6%), and the median age was 41 years. The main 
causes of CKD were glomerulonephritis, nephritis, and pyelonephritis (19.8%), with secondary 
causes of hypertension/cardiovascular diseases (17.8%). A considerable number of patients 
(49.2%) had an indeterminate diagnosis, which limited the etiological analysis. The most 
common type of transplant was from a living donor (54.5%), and the mean pre-transplant 
dialysis period was 47 months. During follow-up, there were 2,212 (15.3%) graft losses (7.0% 
deaths, 2.3% re-transplants and 6.0% returning to dialysis for more than three months) and 
11,699 (84.7%) censorings occurred (Table 1). 
 
There were more women in the cyclosporine group than in the tacrolimus group (64.8% vs. 
56.8%; p<0.001). The distribution of patients among the age groups was significantly different; 
however, the mean patient age in the cyclosporine and tacrolimus groups was not significantly 
different (41.16±12.06 and 41.42±12.57 years, respectively; p=0.231). Among patients who 
received deceased-donor grafts, tacrolimus was used more frequently (63.1%) than 
cyclosporine (36.9%) (p<0.001) (Table 1). Mycophenolate (mofetil or sodium) was the most 
commonly used anti-proliferative agent in both groups (Table 2).  
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Table 2. Immunosuppressive drug combinations used by the patients in the cohort. Brazil: 
2000-2010 (N= 13,811) 
 
Cyclosporine-Based Immunosuppressive 
Regimens  
Tacrolimus-Based Immunosuppressive 
Regimens 
Regimen n 
 
Regimen n 
Cyclosporine (monotherapy) 539   Tacrolimus (monotherapy) 216 
Cyclosporine + azathioprine 1322 
 
Tacrolimus + azathioprine 939 
 
+ mycophenolate 577   
 
+ mycophenolate 587 
 
+ mycophenolate/sirolimus 143 
  
+ mycophenolate/sirolimus 132 
 
+ 
mycophenolate/sirolimus/everol
imus 
2   
 
+ 
mycophenolate/sirolimus/everol
imus 
0 
 
+ mycophenolate/everolimus 6 
  
+ mycophenolate/everolimus 27 
 
+ sirolimus 94   
 
+ sirolimus 39 
 
+ sirolimus/everolimus 1 
  
+ sirolimus/everolimus 3 
 
+ everolimus 4   
 
+ everolimus 7 
Cyclosporine + mycophenolate 2595 
 
Tacrolimus + mycophenolate 4795 
 
+ sirolimus 433   
 
+ sirolimus 907 
 
+ sirolimus/everolimus 8 
  
+ sirolimus/everolimus 19 
 
+ everolimus 38   
 
+ everolimus 121 
Cyclosporine + sirolimus 83 
 
Tacrolimus + sirolimus 119 
 
+everolimus 0   
 
+ everolimus 0 
Cyclosporine + everolimus 42 
 
Tacrolimus + everolimus 13 
Total  5887   Total  7924 
 
The univariate analysis indicated a higher risk of graft loss among patients treated with 
tacrolimus (HR=1.369; 95% CI 1.253±1.495) and among male patients (HR=1.107; 1.007±
1.218). The risk of graft loss increased for each additional year of age of the recipient 
(HR=1.015; 1.011±1.023) and was higher among those who underwent pre-transplantation 
dialysis for more than 47 months (HR=1.741; 1.591±1.906) and among those who received 
transplants between 2005-2009 (HR= 1.465; 1.323±1.624). The patients who received a 
deceased-donor organ also had a higher risk of graft loss (HR=1.926; 1.767±2.101) and, 
similarly, those patients with diabetes as the primary cause of CKD (HR=1.494; 1.242±1.796). 
(Table 3). A graphic representation of survival according to the explanatory variables is shown 
in Figure 1.  
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Table 3. Hazard ratio for graft loss by demographic and clinical characteristics of the study 
population. Brazil: 2000-2010 (N=13,811) 
 
Variable 
Total 
Graft loss 
HR (95% CI) P Total Death 
Dialysis for 
more than 
3 
months/re-
transplant 
n n % n % n % 
Sex 
 
  
 
 
 
 
 
 
Female  8.316 
1,25
3 
15.6 607 48,4 646 51.6 0.991 (0.9089±1.081) 0.845 
Male 5.495 859 15.1 360 41.9 499 58.1 1.0  
           
Age at transplantation 
(additional year) 
13,811       1.015 (1.011±1.023) <0.001 
           
Primary cause of Chronic 
Kidney Disease 
         
Diabetes Mellitus 648 129 19.9 80 62.0 49 38.0 1.494 (1.242±1.796) <0.001 
Hypertension / 
Cardiovascular Disease 
2.453 432 17.6 199 46.1 233 53,9 1.114 (0.994±1.249) 0.064 
Nephritisa 2.740 488 17.8 188 38.5 300 61,5 1.053 (0.943±1.176) 0.356 
 Organ failure or rejection 737 73 9,91 41 56.2 32 43.8 0.679 (0.535 ±0.810) <0.001 
Uropathies 194 27 13.9 8 29.6 19 70,4 0.919 (0.627±1.347) 0.665 
Kidney cystic disease/ 
Neoplasms / Tumors 
278 45 16.2 24 53.3 21 46.7 1.062 (0.788±1.433) 0.689 
Undetermined / Other causes 6.761 918 13.6 427 46.5 491 53.5 0.959 (0.873±1.053) 0.380 
           
Calcineurin inhibitor          
Tacrolimus 7.924 
1.07
1 
13.5 455 42.5 616 57.5 1.369 (1.253±1.495) <0.001 
Cyclosporine 5.887 
1.04
1 
17.7 512 49.2 529 50.8 1.0  
           
Donor type          
Deceased 
6.284 
1.18
8 
18.9 556 46.8 632 53.2 1.926 (1.767±2.101) <0.001 
Living 7.527 924 12.3 411 44.5 513 55.5 1.0  
  
 
       
 
Time on dialysis prior to 
transplantation (months)  
       
 
> 47  5.817 1008 17,3 459 45.5 549 54.5 1.741 (1.591±1.906) <0.001 
47 5.801 
 
944 
 
16.3 
 
435 
 
46.1 
 
509 
 
53.9 
1.0  
 
 
        
Year of transplantation 
 
        
Year 2005 a 2009 7.646 793 10.4 397 50.1 396 49.9 1.465 ( 1.323 ± 1.624) <0.001 
Year 2000 a 2004 6.165 
1.31
9 21.4 570 43.2 749 56.8 
1.0  
          
a Glomerulonephritis / Interstitial nephritis / pyelonephritis. 
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Figure 1. Kaplan-Meier graft survival estimates for 10 years after renal transplantation 
according to calcineurin inhibitor, time on dialysis prior to transplantation, and CKD primary 
diagnosis. 
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The Kaplan-Meier curves for the subgroup analysis of living or deceased donors among the 
cyclosporine and tacrolimus groups are shown in Figure 2. This analysis revealed a significant 
difference in favor of cyclosporine in both groups. To evaluate the impact of death on graft 
survival, we performed a death-censored graft loss analysis. Even in this scenario, tacrolimus 
failed to demonstrate a therapeutic advantage (log rank test p<0.001. 
 
Figure 2. Kaplan-Meier curves of tacrolimus and cyclosporine comparisons by living or 
deceased donor for 10 years after renal transplantation. 
 
 
The overall 10-year graft survival was 69.5% (95% CI 68.0±71.1). Graft survival among patients 
treated with cyclosporine or tacrolimus was 71.9% (71.5±75.0) and 64.8% (60.1±70.0), 
respectively. The overall graft survival per drug group per follow-up year is shown in Table 4.  
 
Table 4. Annual graft survival rates of the study population according to the calcineurin inhibitor 
used. Brazil: 2000-2010 (N=13,811). 
 
Follow-up 
year 
Relative risk (95%CI) 
Total 
Cyclosporine-based 
regimens 
Tacrolimus-based 
regimens 
1st 0.976 (0.973 - 0.978) 0.982 (0.978 - 0.985) 0.971 (0.968 - 0.975) 
2nd 0.944 (0.940 - 0.948) 0.954 (0.949 - 0.960) 0.936 (0.931- 0.942) 
3rd 0.913 (0.908 - 0.918) 0.929 (0.922 - 0.936) 0.899 (0.892 - 0.907) 
4th 0.885 (0.879 - 0.891) 0.904 (0.896 - 0.912) 0.867 (0.857 - 0.876) 
5th 0.853 (0.846 - 0.860) 0.875 (0.866 - 0.884) 0.830 (0.819 - 0.842) 
6th 0.819 (0.810 - 0.827) 0.844 (0.834 - 0.855) 0.788 (0.774 - 0.802) 
7th 0.783 (0.774 - 0.793) 0.812 (0.800 - 0.824) 0.745 (0.728 - 0.762) 
8th 0.752 (0.741 - 0.763) 0.778 (0.765 - 0.791) 0.715 (0.696 - 0.735) 
9th 0.723 (0.710 - 0.735) 0.748 (0.733 - 0.763) 0.691 (0.668 - 0.714) 
10th 0.695 (0.680 - 0.711) 0.719 (0.701 - 0.737) 0.648 (0.601 - 0.700) 
 
The multivariate analysis revealed that the following variables were associated with a higher risk 
of graft loss: use of tacrolimus (HR=1.194; 95% CI 1.082±1.318), deceased donor 
transplantation (HR=1.604; 1.455±1.769), additional year of age of the recipient (HR=1.008; 
1.004±1.012), median period of pre-transplantation dialysis greater than 47 months (HR=1.351; 
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1.224±1.491), diagnosis of diabetes as the primary cause of CKD (HR=1.333; 1.109±1.604) and 
transplantation year between 2005 and 2009 (HR= 1.266; 1.128±1.422) (Table 5).  
 
Table 5. Hazard ratio for graft loss: Cox logistic regression of 10-year follow-up. Brazil: 2000-
2010 (N=13,811).  
 
Variable HR (95%CI) P 
Calcineurin inhibitor (tacrolimus-based regimens) 1.194 (1.082±1.318) <0.001 
Donor type (deceased) 1.604 (1.455±1.769) < 0.001 
Age (additional year) 1.008 (1.004±1.012) <0.001 
Time on dialysis prior to transplantation (>47 months) 1.351 (1.224±1.491) <0.001 
Primary cause of Chronic Kidney Disease (Diabetes Mellitus) 1.333 (1.109±1.604) 0.002 
Year of transplantation (2005 a 2009) 1.266 (1.128±1422) <0.001 
 
Discussion 
 
With this study, we aimed to evaluate the long-term effectiveness of maintenance 
immunosuppression in kidney transplantation at the national level. Consequently, we conducted 
a deterministic-probabilistic linkage of SUS administrative databases and extracted a cohort of 
transplanted patients. The 10-year graft survival of 69.5% was influenced by both clinical and 
demographic characteristics.   
 
Our results revealed an increase in the number of transplantations in Brazil and indicated a 
worst graft survival for patients undergoing transplantation between 2005 to 2009, although 
there were no major changes in the guidelines and procedures between 2000 and 2009 in 
Brazil(15,16). Our results also indicated a higher concentration in more developed regions of the 
country, as previously reported by others(17). Glomerulonephritis, nephritis, and pyelonephritis, 
along with hypertension and diabetes mellitus, were the leading causes of CKD, which is similar 
to our previous study as well as other published studies(26, 10, 32).  
 
Our cohort also showed that 4.7% of SDWLHQWVKDG³GLDEHWHV´UHJLVWHUHGDVWKHLUSULPDU\FDXVH
of CKD. The International Diabetes Federation reported a prevalence of diabetes of 6.4% in 
Brazil in 2010, the last year of our cohort study(33). A former study of the SUS databases in 
Brazil revealed a prevalence of 16% among patients in dialysis (34) .This is important as diabetes 
is associated with poorer outcomes(35). This difference between patients in our study and 
undergoing dialysis may be explained by the fact that some patients with diabetes, who are 
undergoing dialysis, will present with a clinical status that precludes transplantation as an 
option. However, future studies are needed to more accurately determine the reason for the 
lower transplantation rate among patients with diabetes in Brazil. 
 
Among the demographic variables, age influenced graft survival, considered here as death, re-
transplantation or a return to dialysis. Gender did not influence graft survival in our study. 
However recent studies have suggested men have a higher risk of graft loss compared with 
women in the long term(11,36-38).  
 
The distribution of transplants according to age group in Brazil between 2000 and 2010 
corresponds with the profile of the patients waiting on the kidney transplant list (39). This 
distribution includes fewer ROGHUSDWLHQWV\HDUVZKRDUHOHVVOLNHO\WREHRQWKHZDLWLQJOLVW
and who spend more time on dialysis before entering the list(39). Consequently, only 2.6% of the 
transplantations were performed in older people. Although older age has been identified as a 
risk factor for graft loss in this and other studies(26, 37, 40), some authors have questioned this 
assumption and have reported that the survival rates of patients aged <50 years were similar to 
those of patients aged >50 years(12, 41). As a result, we believe age should not necessarily be a 
discriminatory factor against receiving a transplant.  
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Among the clinical variables, a median period of dialysis greater than 47 months, a diagnosis of 
diabetes mellitus as the primary cause of CKD, donor type, and the specific calcineurin inhibitor 
affected graft survival in our study. This is in agreement with other studies that found a longer 
dialysis period and a diagnosis of diabetes are predictors of poor prognosis in kidney 
transplantation(40, 42). A further study demonstrated that patients with diabetes exhibited an 
increased risk of post-transplantation cardiovascular events, all-cause death, and death from 
cardiovascular causes compared with those without diabetes(35). Consequently, additional care 
is needed with these patients. 
 
In our cohort, the use of tacrolimus increased over time coincided with an increase in the 
number of deceased donor transplants. More graft loss events occurred with cyclosporine; 
however, the time until the event (the survival time) were worse for tacrolimus compared with 
cyclosporine (Figures 1 and 2). In addition, the Kaplan-Meier curves in the subgroup analysis of 
living or deceased donors within the tacrolimus and cyclosporine groups showed that tacrolimus 
failed to demonstrate a therapeutic advantage, regardless of donor type (Figure 2). Additionally, 
in the death-censored graft loss analysis, tacrolimus did not present an advantage over 
cyclosporine. 
 
Furthermore, the final multivariate model, which was adjusted for other variables, including 
donor type, showed poorer graft survival rates in patients treated with tacrolimus compared with 
those treated with cyclosporine after a 10-year follow-up (survival rates of 64.8% and 71.9%, 
respectively). This is in agreement with the study by Bunnapradist et al.(43) involving 7,079 
patients treated with tacrolimus or cyclosporine, both in combination with mycophenolate, which 
showed a higher risk of treatment failure with tacrolimus (HR=1.28; 95% CI 1.09-1.49). In our 
study, the residual analysis indicated a good fit based on the procedure proposed by 
Schoenfeld, with a mean value close to zero and no violation of the homoscedasticity 
assumption. 
 
Studies from different countries have evaluated the outcomes of kidney transplantation using 
tacrolimus or cyclosporine according to donor type and other variables. In the United States, the 
two-year survival rate of 7,079 living donor graft recipients was 94.3% among patients treated 
with cyclosporine and 92.2% among those treated with tacrolimus(43). Considering only 
deceased donor graft recipients, a study conducted in the United States with more than 50,000 
patients reported that the five-year graft survival was similar between patients who received 
cyclosporine- or tacrolimus-based regimens(44). Similar results were obtained in a previous study 
in the United States using a paired analysis of deceased donor transplants with a five-year 
follow-up(45) and in a Saudi Arabian study with a two-year follow-up(46).  
 
Overall our findings with this longer-term follow-up of patients, combined with the findings from 
other countries involving longer-term follow-up, indicate that the rationale for the preferred use 
of tacrolimus in kidney transplant patients is not supported by the clinical data. Consequently, 
other factors associated with this practice should be investigated especially if they lead to higher 
costs and worse outcomes for patients. In the meantime, SUS should consider prescribing 
restrictions for tacrolimus versus cyclosporine to improve patient outcomes following 
transplantation as well as save resources, with tacrolimus currently costing up to three times for 
SUS patients in Brazil than cyclosporine. 
 
The major limitation of this study is that it involves the use of administrative databases. As a 
result, information was not available on several factors that influence short- and long-term graft 
survival, including acute rejection rates, immunological compatibility, ischemia time, serum 
creatinine levels and graft function, as well as the specific causes of graft loss. In addition, blood 
levels of immunosuppressants were not available. However the Clinical Protocol and 
Therapeutic Guidelines of the Brazilian Ministry of Health recommend drug level monitoring, 
and SUS pays for these procedures. Another limitation involves the comparison of tacrolimus 
and cyclosporine independently of adjuvant medicines as the Clinical Protocol and Therapeutic 
Guidelines of the Brazilian Ministry of Health recommends a triple-drug regimen as 
maintenance immunosuppressive treatment. 
 
Furthermore, data from administrative records might have been incomplete or contain 
inconsistencies inherent with the retrospective nature of the study. Despite these limitations, we 
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believe our findings are valid as these were obtained using a long-term nationwide 
observational study involving more than 13,000 patients. In addition, this reflects the real world 
situation in Brazil.  
 
In conclusion, our study showed that among other factors, the use of tacrolimus-based 
regimens was associated with worse graft survival. As a result, as mentioned, SUS should 
potentially consider prescribing restrictions for tacrolimus in Brazil especially given the cost 
differential with cyclosporine. 
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Key issues 
 
x Chronic kidney disease (CKD) is characterized by slow, progressive, and irreversible loss of 
kidney function. For patients with no contraindications transplantation is the renal 
replacement therapy of choice for patients with end-stage renal failure.  
 
x Immunosuppression regimens supplied by Unified Health System (Sistema Único de 
Saúde, SUS), which provides more than 95% of all kidney transplants in Brazil, consists of 
a triple-drug regimen, typically containing a corticosteroid, a calcineurin inhibitor 
(cyclosporine or tacrolimus), and an antiproliferative agent. Calcineurin inhibitors have been 
considered the hallmark immunosuppression. However in Brazil, tacrolimus costs three 
times more than cyclosporine. 
 
x The overall 10-year graft survival in our study was 69.5% (95% CI 68.0±71.1) with graft 
survival among patients treated with cyclosporine- or tacrolimus-based regimens was 
71.9% (70.1±73.7) and 64.8% (60.1±70.0), respectively. The use of tacrolimus-based 
regimens increased the risk of graft loss, defined as death or return to dialysis, in 
comparison with the use of cyclosporine-based regimens in 10 years of follow-up 
(HR=1.194; 95% CI 1.082±1.318). 
 
x Analysis per donor type (living or deceased) revealed no advantage of the use of tacrolimus 
in both groups. 
 
x The rationale for the preferred use of tacrolimus in Brazil and other countries is not 
supported by the literature or our findings. Future research should look at the factors 
associated with this practice especially since if thisleads to higher costs and worse 
outcomes for patients 
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